Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 26 out of 100. Risk genes beyond APOE

Topic: Brain proteins, microglia and lab models

Plain-language summary

Con el envejecimiento de la población general, el número de pacientes con epilepsia de inicio tardío crece constantemente. Este hecho tiene especial relevancia porque la evidencia actual sugiere que una proporción de estos casos puede estar asociada con enfermedades neurodegenerativas, en particular con la enfermedad de Alzheimer (EA) (1). Las proteínas beta amiloide (?A) y tau, distintivas de la EA y presentes años antes de la aparición de los síntomas clínicos de la enfermedad, podrían desempeñar un papel en el desarrollo de la hiperexcitabilidad neuronal. El riesgo de crisis epilépticas es mayor en pacientes con EA autosómica dominante. Se ha reportado una frecuencia de crisis epilépticas del 47,7?%, después de un seguimiento medio de 8,4 años en pacientes con EA que albergaban una mutación patógena en presenilina (PSEN)1, PSEN2 y en la proteína precursora amiloide (PPA) o duplicaciones de esta. Un metaanálisis mostró que el alelo ?4 de la apolipoproteína E es un factor de riesgo para la epilepsia. Además, se ha demostrado que los pacientes con EA más jóvenes tienen más probabilidades de tener crisis epilépticas no provocadas, con un aumento de hasta 87 veces en el grupo de edad de 50 a 59 años, en comparación con la población general de la misma edad. Por lo tanto, la epilepsia es una comorbilidad frecuente en la EA de inicio temprano. Asimismo, los pacientes con EA presentan un mayor riesgo de desarrollar epilepsia durante el curso de la enfermedad y diversos estudios manifiestan que la epilepsia de inicio tardío puede representar la primera manifestación clínica de la EA. Dependiendo del grado de deterioro cognitivo, se describen distintas formas de epilepsia dentro del espectro de la EA (figura 1). La llamada “variante epiléptica” de la EA ha despertado un creciente interés clínico y de investigación, y se refiere a aquellos casos en los que se producen crisis epilépticas, incluso cuando el deterioro cognitivo está ausente o es mínimo, es decir, no se evidencia deterioro en la evaluación neuropsicológica. En este sentido, a veces se considera una forma “no cognitiva” de presentación de la EA, en la que las crisis epilépticas constituyen el signo inaugural y aislado.

What this study adds

Evidence grade: Low

This review describes epilepsy as a frequent comorbidity in early-onset Alzheimer's disease and notes that late-onset epilepsy may sometimes be the first clinical sign of Alzheimer's disease. It addresses recognition of seizures in the Alzheimer's spectrum rather than a cure or prevention.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Bombón-Albán, P. E., & Salazar, J. V. S. (2025). Epilepsia como manifestación temprana en el espectro de la enfermedad de Alzheimer: explorando la variante epiléptica. Acta neurológica colombiana. https://doi.org/10.22379/anc.v41i4.2037

Vancouver

Bombón-Albán PE, Salazar JVS. Epilepsia como manifestación temprana en el espectro de la enfermedad de Alzheimer: explorando la variante epiléptica. Acta neurológica colombiana. 2025. doi:10.22379/anc.v41i4.2037.

BibTeX

@article{bombonalban2025-5d13b644,
  author  = {Bombón-Albán, Paulina Elizabeth and Salazar, Johanna Vanessa Suárez},
  title   = {{Epilepsia como manifestación temprana en el espectro de la enfermedad de Alzheimer: explorando la variante epiléptica}},
  journal = {Acta neurológica colombiana},
  year    = {2025},
  doi     = {10.22379/anc.v41i4.2037},
  url     = {https://doi.org/10.22379/anc.v41i4.2037}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.

Key findings

Why it matters

This review describes epilepsy as a frequent comorbidity in early-onset Alzheimer's disease and notes that late-onset epilepsy may sometimes be the first clinical sign of Alzheimer's disease. It addresses recognition of seizures in the Alzheimer's spectrum rather than a cure or prevention.

Study details

How this study scored 26/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 0 of 4; Study design 0 of 12; Strength of evidence 1 of 5; Peer-review validation 10 of 10; How recent 4 of 5; Sample size 0 of 4; Effect reported 0 of 3; Studied in people 0 of 3; Randomized / blinded 0 of 2; Times cited 0 of 7; Citations per year 0 of 5; Impact for its field and year 0 of 6; Cited by studies here 0 of 6; Still being cited 0 of 4; Senior author's track record left out, no data; Institution's track record 0 of 3; Multicenter collaboration 0 of 3; Indexed in PubMed 1 of 2; Free to read 2 of 2. 25 of the 96 points it could be judged on, which is 26 of 100. Total 26 of 100.25 of the 96 points we could judge = 26 of 100

Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it. We have no data on senior author's track record, so that was left out: it earned 25 of the 96 points we could judge it on, which is 26 out of 100.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (Acta neurológica colombiana)
Journal's citation record 0 / 4 Acta neurológica colombiana: journal h-index 11 (OpenAlex, 2026-10-29)
Study design 0 / 12 No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence 1 / 5 Rated “low” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 4 / 5 2025 — within 3 year(s) of the newest study here
Sample size 0 / 4 Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 0 / 3 Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 0 / 7 Cited 0 times (OpenAlex, 2026-10-10)
Citations per year 0 / 5 0.0 citations a year over 3 year(s) since 2025
Impact for its field and year 0 / 6 Cited 0.0× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 0 / 6 No other study in this library cites it
Still being cited 0 / 4 Cited 0 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record — / 4 OpenAlex's profile for last-listed author Johanna Vanessa Suárez Salazar holds only 6 work(s), too few to judge a track record — left out of this score
Institution's track record 0 / 3 Pontificia Universidad Católica del Ecuador Sede Ambato: institution h-index 24 (OpenAlex)
Multicenter collaboration 0 / 3 OpenAlex lists 1 institution(s) in 1 country — scores zero (affiliation lists can be incomplete)
Indexed in PubMed 1 / 2 Not in PubMed, but has a DOI
Free to read 2 / 2 Free to read
Points 25 / 96 Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 25 of the 96 points we could judge it on is 26 out of 100.
Total 26 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here.

Related studies in Risk genes beyond APOE from nearby years

Also tagged “lewy”

1,017 studies in the library carry the topic tag “lewy”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,017 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Risk genes beyond APOE

See all studies in Risk genes beyond APOE →